| 1 |
Li J,Yen C,Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer[J]. Science, 1997, 275(5308):1943-1947.
|
| 2 |
Steck PA,Pershouse MA,Jasser SA, et al. Identification of a candidate tumour suppressor gene,MMAC1,at chromosome I0q23.3 that is mutated in multiple advanced cancers[J]. Nat Genet, 1997, 15(4):356-362.
|
| 3 |
Li DM,Sun H. TEP1, Encoded by a candidate tumor suppressor locus,is a protein tyrosine phosphatase regulated by transforming growth factor beta[J]. Cancer Res, 1997, 57(11):2124-2129.
|
| 4 |
Vazquez F,Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling[J]. Biochim Biophys Acta, 2000, 1470(1):M21-M35.
|
| 5 |
Simpson L,Parsons R. PTEN: life as a tumor suppressor[J]. Exp Cell Res, 2001, 264(1):29-41.
|
| 6 |
Lee JO,Yang H,Georgescu MM, et al. Crystal structure of the PTEN tumor suppress:implications for its phosphoinositide phosphatase activity and membrane association[J]. Cell, 1999, 99(3):323-334.
|
| 7 |
Tamura M,Gu J,Takino T, et al. Tumor suppressor PTEN inhibition of cell invasion,migration,and growth:differential involvement of focal adhesion kinase and p130Cas[J]. Cancer Res, 1999, 59(2):442-449.
|
| 8 |
Smith IN,Briggs JM. Structural mutation analysis of PTEN and its Genotype-Phenotype correlations in endometriosis and cancer[J]. Proteins, 2016, 84(11):1625-1643.
|
| 9 |
Hesson LB,Packham D,Pontzer E, et al. A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines[J]. Biol Proced Online, 2012, 14(1):5.
|
| 10 |
Poliseno L,Pandolfi PP. PTEN ceRNA networks in human cancer[J]. Methods, 2015, 77-78:41-50.
|
| 11 |
Ioffe YJ,Chiappinelli KB,Mutch DG, et al. Phosphatase and tensin homolog (PTEN) pseudogene expression in endometrial cancer: A conserved regulatory mechanism important in tumorigenesis?[J]. Gynecol Oncol, 2012, 124(2):340-346.
|
| 12 |
Poliseno L,Salmena L,Zhang J, et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology[J]. Nature, 2010, 465(7301):1033-1038.
|
| 13 |
Poliseno L,Haimovic A,Christos PJ, et al. Deletion of PTENP1 pseudogene in human melanoma[J]. J Invest Dermatol, 2011, 131(12):2497-2500.
|
| 14 |
Liu J,Xing Y,Xu L, et al. Decreased expression of pseudogene PTENP1 promotes malignant behaviours and is associated with the poor survival of patients with HNSCC[J]. Sci Rep, 2017, 7:41179.
|
| 15 |
Qin X. Yan L,Zhao X, et al. microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer[J]. Oncol Lett, 2012, 4(6):1290-1296.
|
| 16 |
Kovalenko TF,Sorokina AV,Ozolinya LA, et al. Methylation of the pseudogene PTENP1 5'-terminal region in endometrial cancer and hyperplasia[J]. Russ J Bioorg Chem, 2013, 39(4):397-405.
|
| 17 |
Masunaga A,Omatsu M,Kunimura T, et al. Expression of PTEN and its pseudogene PTENP1, and promoter methylation of PTEN in non-tumourous thymus and thymic tumours[J]. J Clin Pathol, 2017, 70(8):690-696.
|
| 18 |
Chen CL,Tseng YW,Wu JC, et al. Suppression of hepatocellular carcinoma by baculovirus-mediated expression of long non-coding RNA PTENP1 and MicroRNA regulation[J]. Biomaterials, 2015, 44(9):71-81.
|
| 19 |
Li RK,Gao J,Guo LH, et al. PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer[J]. Cancer Gene Ther, 2017, 24(7):309-315.
|
| 20 |
Zhang R,Guo Y,Ma Z, et al. Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer[J]. Oncotarget, 2017, 8(16):26079-26089.
|
| 21 |
Gao L,Ren W,Zhang L, et al. PTENp1, a natural sponge of miR-21, mediates PTEN expression to inhibit the proliferation of oral squamous cell carcinoma[J]. Mol Carcinog, 2017, 56(4):1322-1334.
|
| 22 |
Johnsson P,Ackley A,Vidarsdottir L, et al. A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells[J]. Nat Struct Mol Biol, 2013, 20(4):440-446.
|
| 23 |
Kovalenko TF,Sorokina AV,Ozolinia LA, et al. Pseudogene PTENP1 5'-region methylation in endometrial cancer and hyperplasias[J]. Bioorg Khim, 2013, 39(4):445-453.
|
| 24 |
Bokhman JV. Two pathogenetic types of endometrial carcinoma[J]Gynecol Oncol, 1983, 15(1):10-17.
|
| 25 |
Silverberg SG, KurmanRJ, Nogales F, et al, Epithelialtumours and relatedlesions[M] . lyon: iarc press, 2003: 217-232.
|
| 26 |
Pavlidou A,Vlahos NF. Molecular alterations of PI3K/AKT/mTOR pathway: a therapeutic target in endometrial cancer[J]. ScientificWorldJournal, 2014, 2014:709736.
|
| 27 |
Huang HN,Lin MC,Tseng LH, et al. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression[J]. Histopathology, 2015, 66(4):517-528.
|
| 28 |
Kanamori Y,Kigawa J,Itamochi H, et al. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy[J]. Int J Cancer, 2002, 100(6):686-689.
|
| 29 |
Tashiro H,Blazes MS,Wu R, et al. Mutations in PTEN are frequent in endomctrial carcinoma but rare in other common gynecological malignancies[J]. Cancer Res, 1997, 57(18):3935-3940.
|
| 30 |
Dong P,Konno Y,Watari H, et al. The impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer[J]. J Transl Med, 2014, 12:231.
|
| 31 |
Polivka J Jr,Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther, 2014, 142(2):164-175.
|
| 32 |
Slomovitz BM,Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer[J]. Clin Cancer Res, 2012, 18(21):5856-5864.
|
| 33 |
Bing L,Hong C,Li-Xin S, et al. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression[J]. Arch Gynecol Obstet, 2014, 290(3):533-541.
|
| 34 |
Tamura M,Gu J,Matsumoto K, et a1. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN[J]. Science, 1998, 280(5369):1614-1617.
|
| 35 |
Zhang LL,Liu J,Lei S, et al. PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression[J]. Cell Signal, 2014, 26(5):1011-1020.
|
| 36 |
Dragoj M,Bankovic J,Sereti E, et al. Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors[J]. Invest New Drugs, 2017, 35(6):718-732.
|
| 37 |
Waite KA,Eng C. Protean PTEN:from and funcdon[J]. Am J Hum Genet, 2002, 70(4):829-844.
|
| 38 |
Diao L,Chen YG. PTEN, a general negative regulator of cyclin D expression[J]. Cell Res, 2007, 17(4):291-292.
|
| 39 |
Yart A,Laffargue M,Mayeux P, et al. A critical role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor[J]. J Biol Chem, 2001, 276(12):8856-8864.
|
| 40 |
Weng LP,Smrrh WM,Brown JL, et al. PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model[J]. Hum Mol Genet, 2001, 10(6):605-616.
|
| 41 |
Raouf A E, Ibrahim TR. Expression and significance of PTEN and GLUT-1 in proliferative endometrium, endometrial hyperplasia, and endometrioid adenocarcinoma[J]. Egypt J Patho, 2014, 34(2):117-124.
|
| 42 |
Sal V,Demirkiran F,Erenel H, et al. Expression of PTEN and β-catenin and their relationship with clinicopathological and prognostic factors in endometrioid type endometrial cancer[J]. Int J Gynecol Cancer, 2016, 26(3):512-520.
|
| 43 |
Akiyama-Abe A,Minaguchi T,Nakamura Y, et al. Loss of PTEN expression is an Independent predictor of favourable survival in endometrial carcinomas[J]. Br J Cancer, 2013, 109(6):1703-1710.
|
| 44 |
鲁晓东,卢房利,段钊, 等. TTF-1和PTEN基因在子宫内膜癌早期病变中的表达意义[J]. 昆明医科大学学报, 2017 (8):62-66.
|
| 45 |
Wu Y,Wang YQ,Weng WW, et al. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls[J]. Oncogenesis, 2016, 5:e192.
|
| 46 |
Dong L,Qi P,Xu MD, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls[J]. Int J Cancer, 2015, 137(5):1128-1135.
|
| 47 |
Yu G,Yao W,Gumireddy K, et al. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress Clear-Cell renal cell carcinoma progression[J]. Mol Cancer Ther, 2014, 13(12):3086-3097.
|
| 48 |
Gong T,Zheng S,Huang S, et al. PTENP1 inhibits the growth of esophageal squamous cell carcinoma by regulating SOCS6 expression and correlates with disease prognosis[J]. Mol Carcinog, 2017, 56(12): 2610-2619.
|
| 49 |
Mitamura T,Dong P,Ihira K, et al. Molecular-targeted therapies and precision medicine for endometrial cancer[J]. Jpn J Clin Oncol, 2018. doi: 10.1093/jjco/hyy159. [Epub ahead of print] |